Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksVRP.L Regulatory News (VRP)

  • There is currently no data for VRP

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Verona Pharma plc: TR-1: Standard form for notification of major holdings

7 Aug 2020 15:46

Verona Pharma plc: TR-1: Standard form for notification of major holdings

LONDON and RALEIGH, N.C., Aug. 07, 2020 (GLOBE NEWSWIRE) --

NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible)i
 
1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attachedii:Verona Pharma plc
1b. Please indicate if the issuer is a non-UK issuer (please mark with an “X” if appropriate)
Non-UK issuer 
2. Reason for the notification (please mark the appropriate box or boxes with an “X”)
An acquisition or disposal of voting rightsX
An acquisition or disposal of financial instruments 
An event changing the breakdown of voting rightsX
Other (please specify)iii: 
3. Details of person subject to the notification obligationiv
NameGrowth Equity Opportunities Fund IV, LLC Growth Equity Opportunities 17, LLC
City and country of registered office (if applicable)Delaware, United States
4. Full name of shareholder(s) (if different from 3.)v
Name 
City and country of registered office (if applicable) 
5. Date on which the threshold was crossed or reachedvi:22/07/2020
6. Date on which issuer notified (DD/MM/YYYY):06/08/2020
7. Total positions of person(s) subject to the notification obligation
 % of voting rights attached to shares (total of 8. A)% of voting rights through financial instruments (total of 8.B 1 + 8.B 2)Total of both in % (8.A + 8.B)Total number of voting rights of issuervii
Resulting situation on the date on which threshold was crossed or reached9.86% (Aggregated - see Section 11)N/A9.86% (Aggregated - see Section 11) 414,545,590
     
Position of previous notification (if applicable)9.86%N/A9.86% 

8. Notified details of the resulting situation on the date on which the threshold was crossed or reachedviii
A: Voting rights attached to shares
Class/type of sharesISIN code (if possible)Number of voting rightsix% of voting rights
Direct(Art 9 of Directive 2004/109/EC) (DTR5.1)Indirect(Art 10 of Directive 2004/109/EC) (DTR5.2.1)Direct(Art 9 of Directive 2004/109/EC) (DTR5.1)Indirect(Art 10 of Directive 2004/109/EC) (DTR5.2.1)
ADSs US925050106440,868,504 (Aggregated - see Section 11) 9.86% (Aggregated - see Section 11) 
     
SUBTOTAL 8. A40,868,5049.86%
B 1: Financial Instruments according to Art. 13(1)(a) of Directive 2004/109/EC (DTR5.3.1.1 (a))
Type of financial instrumentExpiration datexExercise/ Conversion PeriodxiNumber of voting rights that may be acquired if the instrument is exercised/converted.% of voting rights
N/A    
     
     
  SUBTOTAL 8. B 1  
B 2: Financial Instruments with similar economic effect according to Art. 13(1)(b) of Directive 2004/109/EC (DTR5.3.1.1 (b))
Type of financial instrumentExpiration datexExercise/ Conversion Period xiPhysical or cash settlementxiiNumber of voting rights % of voting rights
N/A     
      
      
   SUBTOTAL 8.B.2  

9. Information in relation to the person subject to the notification obligation (please mark the applicable box with an “X”)
Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuerxiii 
Full chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held starting with the ultimate controlling natural person or legal entityxiv (please add additional rows as necessary)X
Namexv% of voting rights if it equals or is higher than the notifiable threshold% of voting rights through financial instruments if it equals or is higher than the notifiable thresholdTotal of both if it equals or is higher than the notifiable threshold
NEA 15 GP, LLC, a limited liability company formed in the State of Delaware, is the general partner of NEA Partners 15, L.P.    
NEA Partners 15, L.P., a limited partnership formed in the State of Delaware, is the general partner of New Enterprise Associates 15, L.P.   
New Enterprise Associates 15, L.P., a limited partnership formed in the State of Delaware, is sole member of Growth Equity Opportunities Fund IV, LLC    
Growth Equity Opportunities Fund IV, LLC is a limited liability company formed in the State of Delaware, United States2.35% N/A2.35% 
    
NEA 17 GP, LLC, a limited liability company formed in the State of Delaware, is the general partner of NEA Partners 17, L.P.    
NEA Partners 17, L.P., a limited partnership formed in the State of Delaware, is the general partner of New Enterprise Associates 17, L.P.   
New Enterprise Associates 17, L.P., a limited partnership formed in the State of Delaware, is sole member of Growth Equity Opportunities 17, LLC   
Growth Equity Opportunities 17, LLC is a limited liability company formed in the State of Delaware, United States7.51%  7.51% 
 
10. In case of proxy voting, please identify:
Name of the proxy holder 
The number and % of voting rights held 
The date until which the voting rights will be held 
 
11. Additional informationxvi
Growth Equity Opportunities 17, LLC purchased 3,888,889 American Depositary Shares (ADSs), representing 31,111,112 Ordinary Shares, from the Issuer on 22 July 2020 as part of the Issuer’s capital raising (the “Financing”) which comprised the issuance of ADSs and Ordinary Shares. Growth Equity Opportunities Fund IV, LLC did not participate in the Financing and so continues to hold 1,219,674 ADSs representing 9,757,392 Ordinary Shares, as previously reported on its TR-1 filed on 8 May 2017. Growth Equity Opportunities Fund IV, LLC (which holds 2.35% voting rights) and Growth Equity Opportunities 17, LLC (which holds 7.51% of voting rights) are acting in concert for the purposes of DTR 5.2.1R(a), consequently their respective holdings are deemed to be aggregated to 9.86% in total. Overall, there has been no increase or decrease from the 9 to 10% voting right threshold that was reported in the previous TR-1 filing of 8 May 2017. However, as explained in this Section 11 there have been changes in the breakdown of how the voting rights are held. It is on this basis that this TR-1 has been completed.

Place of completionUSA
Date of completion7 August, 2020

 

For further information, please contact:

Verona Pharma plcTel: +44 (0) 20 3283 4200
David Zaccardelli, Chief Executive Officerinfo@veronapharma.com
Victoria Stewart, Director of Communications 
  
N + 1 Singer (Nominated Adviser and UK Broker)Tel: +44 (0) 20 7496 3000
Aubrey Powell / George Tzimas / Iqra Amin (Corporate Finance) 
Tom Salvesen (Corporate Broking)
Date   Source Headline
29th Oct 20207:00 amGNWVerona Pharma plc Operational Update and Financial Results for the Three and Nine Months Ended September 30, 2020
28th Oct 202011:01 amGNWVerona Pharma plc : Update on AIM Delisting
23rd Oct 20205:30 pmRNSVerona Pharma
22nd Oct 20207:00 amGNWVerona Pharma to Announce Interim Results for the Three and Nine Months Ended September 30, 2020 and Provide Corporate Update
13th Oct 20207:00 amGNWVerona Pharma to Present Phase 2b COPD Symptom and Quality of Life Data with Ensifentrine at CHEST 2020
23rd Sep 20209:06 amGNWVerona Pharma Initiates Phase 3 Clinical Trials with Nebulized Ensifentrine for the Maintenance Treatment of COPD
21st Sep 20207:00 amGNWIntended Delisting and Cancellation of Ordinary Shares from Trading on AIM
17th Sep 20207:00 amGNWVerona Pharma to Ring the Nasdaq Closing Bell to celebrate $200 million financing
16th Sep 20201:25 pmGNWVerona Pharma Announces Publication of Phase 2b COPD Symptom Data in the International Journal of Chronic Obstructive Pulmonary Disease
8th Sep 20207:00 amGNWVerona Pharma Initiates Pilot Study with pMDI Ensifentrine in U.S. Patients Hospitalized with COVID-19
2nd Sep 20207:00 amGNWVerona Pharma to Present at H.C. Wainwright 22nd Annual Global Virtual Investment Conference
26th Aug 202010:19 amGNWVerona Pharma plc: Grant of RADSUs and PDMR Dealings
24th Aug 20207:00 amGNWVerona Pharma to Present Phase 2b data with Ensifentrine in COPD at the European Respiratory Society International Congress 2020
19th Aug 20207:00 amGNWVerona Pharma Initiates Multiple Dose Part of Phase 2 Clinical Trial with pMDI Formulation of Ensifentrine in COPD
14th Aug 202011:05 amRNSSecond Price Monitoring Extn
14th Aug 202011:00 amRNSPrice Monitoring Extension
14th Aug 20207:00 amGNWVerona Pharma plc Operational Update and Financial Results for the Three and Six Months Ended June 30, 2020
7th Aug 20203:46 pmGNWVerona Pharma plc: TR-1: Standard form for notification of major holdings
4th Aug 20206:13 pmGNWVerona Pharma plc: Issue of Equity, PDMR Dealings & Total Voting Rights
3rd Aug 20207:00 amGNWVerona Pharma Announces August 2020 Virtual Investor Conference Participation
30th Jul 202010:52 amGNWVerona Pharma plc: TR-1: Standard form for notification of major holdings
30th Jul 20207:00 amGNWVerona Pharma to Announce Interim Results for the Three and Six Months Ended June 30, 2020 and Provide Corporate Update
27th Jul 20207:01 amGNWVerona Pharma plc: TR-1: Standard form for notification of major holdings
22nd Jul 20204:50 pmGNWClosing of Financing, Issued Share Capital and Total Voting Rights
17th Jul 20205:47 pmGNWVerona Pharma plc: PDMR Dealings
17th Jul 20207:00 amGNWVerona Pharma Raises $200 Million in Oversubscribed Private Placement and Subscription
6th Jul 20204:04 pmGNWVerona Pharma plc: Issue of Equity and Total Voting Rights
14th May 20207:00 amGNWVerona Pharma Announces FDA Response to End-of-Phase 2 Briefing Package for Ensifentrine in COPD and Outlines Phase 3 ENHANCE Clinical Program
12th May 20201:11 pmGNWDirector/PDMR Shareholding - Grant of Restricted Stock Units, Issue of Equity, Total Voting Rights & PDMR Dealings
1st May 20205:12 pmGNWVerona Pharma Presents Expanded Analysis of Ensifentrine Clinical Data in COPD Maintenance Treatment at the American Thoracic Society 2020 International Conference
30th Apr 20207:00 amGNWVerona Pharma plc: Operational Update and Financial Results for the Three Months Ended March 31, 2020
23rd Apr 20207:00 amGNWVerona Pharma to Announce Financial Results for the Three Months Ended March 31, 2020 and Provide Corporate Update
16th Apr 202012:12 pmGNWVerona Pharma plc: Results of AGM
8th Apr 20207:00 amGNWUpdate on AGM Procedure
31st Mar 20207:00 amGNWVerona Pharma Reports Positive Efficacy and Safety Data with Single Dose pMDI Formulation of Ensifentrine in COPD
20th Mar 202011:28 amGNWVerona Pharma plc: Issue of Equity and Total Voting Rights
17th Mar 20202:06 pmRNSSecond Price Monitoring Extn
17th Mar 20202:01 pmRNSPrice Monitoring Extension
16th Mar 20205:13 pmGNW2019 Annual Report and Accounts and Notice of AGM
5th Mar 20204:01 pmGNWGrant of Restricted Stock Units and PDMR Dealings
27th Feb 20207:00 amGNWVerona Pharma Reports Financial Results for the Full Year Ended December 31, 2019 and Provides Corporate Update
21st Feb 20207:00 amGNWVerona Pharma plc to Announce Financial Results for Full Year Ended December 31, 2019 and Provide Corporate Update
14th Feb 20207:00 amGNWVerona Pharma Announces Publication of Key Phase 2b COPD Data in Respiratory Research
7th Feb 20207:00 amGNWHolding(s) in Company TR-1: Standard form for notification of major holdings
3rd Feb 20207:00 amGNWVerona Pharma Announces Senior Management Changes
28th Jan 20207:00 amGNWVerona Pharma to Present at LSX World Congress 2020
17th Jan 20201:06 pmGNWHolding(s) in Company TR-1: Standard form for notification of major holdings
13th Jan 20204:41 pmRNSSecond Price Monitoring Extn
13th Jan 20204:35 pmRNSPrice Monitoring Extension
13th Jan 20205:00 amGNWVerona Pharma Reports Positive Top-line Data in 4 Week Phase 2b COPD Study with Nebulized Ensifentrine on Top of Tiotropium Therapy

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.